Category: GLP-1 therapy

AT A GLANCE Novo Nordisk wants to prevent compounding pharmacies from making its GLP-1 meds, as they are too complex for manufacturers to make safely, per CNBC. Elaine Chen, Lizzy Lawrence and Ed Silverman at STAT on the FDA’s current flat-spin, on its about-face on shortages of Eli Lilly drug tirzetapide. My favorite weekly news read, The Economist, leads with ‘The everything drugs’ in the

AT A GLANCE On x.com Senator Bernie Sanders said once Ozempic’s exclusivity ends, drug manufacturers could sell generic versions for less than $100 per month. Dr. Daniela Lamas writes on GLP-1 meds in The New York Times, that the drugs’ ‘…numerous benefits are pointing to an emerging cause of so much human disease: inflammation.’ Dr. Lotte Bjerre Knudsen at Novo Nordisk, who led the team that

AT A GLANCE Andrew Joseph at STAT writes from the European Society of Cardiology’s annual meeting in London, that ‘…Wegovy’s the word.’ The Peterson-KFF Health System Tracker writes ‘…over 40% of adults under 65 with private insurance could be indicated for a GLP-1 drug…’ totaling 57.4 million US adults. Quartz reports on BioAge Labs leading drug candidate azelaprag, a pill that mimics apelin, when taken with a

AT A GLANCE STAT notes ‘…Glucose tracking is the future, Dexcom executives gushed at a glitzy launch event…’ A busy week on GLP-1 pricing… first, with NBC News referring to Novo Nordisk CEO Lars Fruergaard Jorgensen defending the high cost of Ozempic and Wegovy in the U.S. Eli Lilly unexpectedly ‘…announced Zepbound 2.5 mg and 5 mg single-dose vials are available… at a 50% or greater

AT A GLANCE Forget Ozempic says Business Insider – an under-the-radar antiaging supplement is the next hot commodity in Hollywood. STAT notes Eli Lilly boosts 2024 revenue guidance by $3 billion, driven by massive sales of Mounjaro and Zepbound. STAT reports an underwhelming earnings report and ongoing questions about increasing competition that sent Novo Nordisk’s shares down. Dr. Scott Kahan says in STAT of online prescribers ‘…The world of obesity and

AT A GLANCE President Biden and Senator Sanders write in USA Today that ‘…Novo Nordisk, Eli Lilly must stop ripping off Americans with high drug prices.’ Foodsmart founder and CEO Dr. Jason Langheier is profiled by Forbes, with his company as ‘…the largest foodcare provider in the United States.’ Lauren J. Young at Scientific American wants to understand how ‘Ozempic Quiets Food Noise in the Brain.’ Not